EFFICACY AND SAFETY OF PHARMACOTHERAPY FOR CHRONIC GASTRITIS
Keywords:
Key words: cytochrome P450, gene polymorphism, MDR-1 gene, CYP2C19 gene, chronic gastritis, personification of pharmacotherapy.Abstract
Resume: The MDR1 gene promotes binding of the cell to the drug, its entry into the cell, and /or efflux into the intercellular space, which explains the development of resistance of the cell to drugs during the expression of this gene. Therefore, the MDR1 gene plays an important role in the effectiveness of pharmacotherapy of various diseases, including HG. The MDR-1 gene encodes the protein P-glycoprotein (translated from the English "permeability" means "permeability"), which is located in the membrane of many normal cells of organs and tissues of the body and regulates the processes of active absorption of drugs through the membrane into the cell. The expression of this protein determines the pharmacokinetics of drugs and, at one time, the effectiveness of pharmacotherapy.
References
1. Arvanitidis, K. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population // К. Arvanitidis, G. Ragia, M. Iordanidou et al.//Fundam. Clin. Pharmacol. 2007. Vol. 21 №4. P. 419 - 426.
2. Efrén Martínez-Quintana, Fayna Rodríguez-González, José María Medina-Gil, Paloma Garay-Sánchez, Antonio Tugores // Actividad de CYP2C19 y factores de riesgo cardiovascular en pacientes con síndrome coronario agudo. Medicina Clínica. Volume 149. Issue 6. 2017. Pages 235-239.
3. Kim K.A., Park P.W., Park J.Y. Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects//Br. J. Clin.Pharmacol. 2007, Jan. Vol.63, №1. P. 53–58.
4. Kim R. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab. Rev., 2012, 34, 47-54.
5. Ochilov A.K., Musayeva D.M. "Treatment of chronic gastritis depending on allelic variants of the CYP2C19 gene" "Topical issues of medical science in the XXI century" Tashkent, 04/25/2019.
6. Ochilov A.K., G.S.Ochilova. "The value of the CYP2C19 gene in pharmacotherapy in chronic gastritis" Problems of Biology and Medicine, 2019, No. 4 (113) 250-252 p.
7. Ochilova G.S., Musaeva D.M. The effect of polymorphism of the MDR1 gene on the effectiveness of treatment of chronic gastritis. //New Day in Medicine 1 (29) 2020.309-312 s.
8. Ochilov A.K., Ochilova G.S. Clinical significance of polymorphisms of the CYP2C19 gene // University science: a look into the future. Collection of scientific papers based on the materials of the International Scientific Conference dedicated to the 85th anniversary of Kursk State Medical University (February 7, 2020) Volume I. 2020. 376-379 P.
9. Klichova F.K., Ochilova G.S. The significance of the MDR-1 gene of pharmacotherapy // Collection of abstracts of the II All-Russian scientific and practical conference with international participation "Safety of pharmacotherapy: NOLI NOCERE!" Kazan, May 16, 2019, pp. 46-47.
10. Ochilov A.K., Ochilova G.S. Clinical significance of polymorphisms of the CYP2C19 gene // Collection of scientific papers based on the materials of the International Scientific Conference "University science: a look into the future" dedicated to the 85th anniversary of Kursk State Medical University. Kursk. February 7, 2020. Volume I. pp. 376-379.
11. Ochilova G. S. Characterization of glycoprotein-P as a drug transporter protein // New day in medicine. 2020. Vol. 2. – No. 30/2. - pp. 60-53
12. Ochilova G.S. The distinguishing feature of the MDR-1 gene for personalization in pharmacotherapy // Collection of abstracts of the III All-Russian scientific and practical conference with international participation "SAFETY OF PHARMACOTHERAPY: NOLI NOCERE!" Kazan. May 21, 2020. pp. 161-162.
13. Musaeva D.M., Ochilova G.S. Personalized pharmacotherapy of chronic gastritis // Materials of the IV All-Russian remote scientific and practical conference with international participation "Pharmacology of different countries" dedicated to the 85th anniversary of Kursk State Medical University and the 75th anniversary of Victory in the Great Patriotic War 1941-1945 Kursk. September 29-30, 2020.
14. Isakov, V.A. Farmakogeneticheskiy analiz metabolizma i klinicheskoy effektivnosti ingibitorov protonnogo nasosa/ V.A.Isakov//Klin. farmakol. ter. 2003. № 1. S. 32 - 37.
15. Kuzuya T., Kobayashi T., Moriyama N., Nagasaka T., Yokoyama I., Uchida K., Nakao A., Nabeshima T. Amlodipine, but not MDR1polymorphisms, alters the pharmacokinetics of cyclosporine A in Japanese kidney transplant recipients//Transplantation. 2003. Vol.76, №5.P. 865–868.
16. Kim K.A., Park P.W., Park J.Y. Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects//Br. J. Clin.Pharmacol. 2007, Jan. Vol.63, №1. P. 53–58.
